(Q36233491)

12 August 2017

1 reference

title

Posaconazole: clinical pharmacology and potential for management of fungal infections (English)

1 reference

12 August 2017

1 reference

2

Thomas J Walsh

1 reference

12 August 2017

Andreas H Groll

1

1 reference

12 August 2017

language of work or name

1 reference

1 August 2005

1 reference

Expert Review of Anti-infective Therapy

12 August 2017

published in

1 reference

12 August 2017

volume

3

1 reference

12 August 2017

issue

4

1 reference

12 August 2017

page(s)

467-487

1 reference

Newer systemic antifungal agents : pharmacokinetics, safety and efficacy

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.467

Disposition of posaconazole following single-dose oral administration in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.467

Mechanism of azole antifungal activity as determined by liquid chromatographic/mass spectrometric monitoring of ergosterol biosynthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.467

Posaconazole is a potent inhibitor of sterol 14alpha-demethylation in yeasts and molds

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.467

In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.467

In vitro activities of the new antifungal triazole SCH 56592 against common and emerging yeast pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.467

In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.467

In vitro activity of three new triazoles and one echinocandin against Candida bloodstream isolates from cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.467

In vitro activities of voriconazole, posaconazole, and four licensed systemic antifungal agents against Candida species infrequently isolated from blood.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.467

Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.467

Antifungal activity of posaconazole compared with fluconazole and amphotericin B against yeasts from oropharyngeal candidiasis and other infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.467

In vitro antifungal susceptibilities of Trichosporon species.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.467

Use of fatty acid RPMI 1640 media for testing susceptibilities of eight Malassezia species to the new triazole posaconazole and to six established antifungal agents by a modified NCCLS M27-A2 microdilution method and Etest

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.467

Activity of the new antifungal triazole, posaconazole, against Cryptococcus neoformans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.467

Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.467

In vitro susceptibilities of cerebrospinal fluid isolates of Cryptococcus neoformans collected during a ten-year period against fluconazole, voriconazole and posaconazole (SCH56592).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.467

Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance P

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.467

Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.467

Activity of posaconazole against Pseudallescheria boydii: in vitro and in vivo assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.467

In vitro activities of four novel triazoles against Scedosporium spp

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.467

In vitro activities of investigational triazoles against Fusarium species: effects of inoculum size and incubation time on broth microdilution susceptibility test results

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.467

In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.467

In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.467

In vitro susceptibilities of zygomycetes to conventional and new antifungals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.467

In vitro activity of posaconazole against clinical isolates of dermatophytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.467

In vitro activities of posaconazole, ravuconazole, terbinafine, itraconazole and fluconazole against dermatophyte, yeast and non-dermatophyte species

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.467

In vitro and in vivo activities of posaconazole against Coccidioides immitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.467

A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.467

A comparative study of the post-antifungal effect (PAFE) of amphotericin B, triazoles and echinocandins on Aspergillus fumigatus and Candida albicans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.467

Application of real-time quantitative PCR to molecular analysis of Candida albicans strains exhibiting reduced susceptibility to azoles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.467

Changes in susceptibility to posaconazole in clinical isolates of Candida albicans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.467

Three-dimensional models of wild-type and mutated forms of cytochrome P450 14alpha-sterol demethylases from Aspergillus fumigatus and Candida albicans provide insights into posaconazole binding.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.467

Mutations in Aspergillus fumigatus resulting in reduced susceptibility to posaconazole appear to be restricted to a single amino acid in the cytochrome P450 14alpha-demethylase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.467

Isolation and in vitro susceptibility to amphotericin B, itraconazole and posaconazole of voriconazole-resistant laboratory isolates of Aspergillus fumigatus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.467

Azole cross-resistance in Aspergillus fumigatus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.467

Interactions between triazoles and amphotericin B against Cryptococcus neoformans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.467

Interactions of posaconazole and flucytosine against Cryptococcus neoformans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.467

Differential activity of triazoles in two-drug combinations with the echinocandin caspofungin against Aspergillus fumigatus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.467

In-vitro activity of nikkomycin Z alone and in combination with polyenes, triazoles or echinocandins against Aspergillus fumigatus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.467

Antifungal triazoles and polymorphonuclear leukocytes synergize to cause increased hyphal damage to Scedosporium prolificans and Scedosporium apiospermum

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.467

Antifungal activities of posaconazole and granulocyte-macrophage colony-stimulating factor ex vivo and in mice with disseminated infection due to Scedosporium prolificans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.467

Pharmacokinetics of SCH 56592, a new azole broad-spectrum antifungal agent, in mice, rats, rabbits, dogs, and cynomolgus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.467

Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.467

Interaction between posaconazole and amphotericin B in concomitant treatment against Candida albicans in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.467

SCH56592 treatment of murine invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.467

Efficacy of SCH56592 in a rabbit model of invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.467

Efficacy of posaconazole in a murine model of central nervous system aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.467

Activity of posaconazole combined with amphotericin B against Aspergillus flavus infection in mice: comparative studies in two laboratories

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.467

Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.467

Antifungal therapy of murine Aspergillus terreus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.467

Effect of granulocyte colony-stimulating factor combination therapy on efficacy of posaconazole (SCH56592) in an inhalation model of murine pulmonary aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.467

Posaconazole therapy of disseminated phaeohyphomycosis in a murine model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.467

Successful therapy of cerebral phaeohyphomycosis due to Ramichloridium mackenziei with the new triazole posaconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.467

Antifungal therapy of experimental cerebral phaeohyphomycosis due to Cladophialophora bantiana

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.467

SCH 56592, amphotericin B, or itraconazole therapy of experimental murine cerebral phaeohyphomycosis due to Ramichloridium obovoideum ("Ramichloridium mackenziei")

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.467

In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.467

Activity of posaconazole in treatment of experimental disseminated zygomycosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.467

Comparison of a new triazole, posaconazole, with itraconazole and amphotericin B for treatment of histoplasmosis following pulmonary challenge in immunocompromised mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.467

Activities of the triazole derivative SCH 56592 (posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.467

Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.467

Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.467

Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.467

Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.467

Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.467

Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of posaconazole (Noxafil).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.467

Use of high-performance liquid chromatographic and microbiological analyses for evaluating the presence or absence of active metabolites of the antifungal posaconazole in human plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.467

Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.467

Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.467

Posaconazole as salvage therapy in patients with chronic granulomatous disease and invasive filamentous fungal infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.467

In vitro activities of terbinafine in combination with fluconazole, itraconazole, voriconazole, and posaconazole against clinical isolates of Candida glabrata with decreased susceptibility to azoles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.4.467

21 January 2018

Identifiers

DOI

10.1586/14787210.3.4.467

1 reference

12 August 2017

1 reference